In a strategic move to expand its footprint in the paediatric and wellness segment, Cipla Limited has announced the acquisition of Inzpera Healthsciences Ltd for ₹110.65 crore.

The acquisition underscores Cipla’s continued focus on diversified consumer healthcare solutions, particularly in the areas of child nutrition, gut health, and wellness. Inzpera, known for its clinically backed, innovative formulations catering to children and adults, operates in segments such as digestive health, respiratory wellness, and nutrition.

According to Cipla, the deal aligns with its broader strategy of strengthening its consumer healthcare and self-care portfolio, leveraging Inzpera’s established product lines and market presence to scale operations across India and other emerging markets.

The company emphasized that Inzpera’s science-led, purpose-driven approach complements Cipla’s mission to make healthcare accessible and holistic, combining prescription excellence with preventive care.

A Cipla spokesperson commented, “This acquisition will help us expand our consumer wellness offerings and further solidify our presence in paediatric and family health — a key area of focus for Cipla’s growth journey.”

Industry analysts view the move as part of Cipla’s ongoing effort to diversify beyond traditional pharmaceuticals and tap into India’s rapidly growing nutraceuticals and OTC healthcare market, projected to exceed ₹65,000 crore by 2030.